AT Bancorp lifted its stake in shares of Celgene Co. (NASDAQ:CELG) by 18.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,381 shares of the biopharmaceutical company’s stock after purchasing an additional 4,144 shares during the period. AT Bancorp’s holdings in Celgene were worth $2,753,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Arcadia Investment Management Corp MI grew its stake in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares in the last quarter. Thompson Davis & CO. Inc. grew its stake in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares in the last quarter. Robecosam AG purchased a new stake in shares of Celgene in the 3rd quarter valued at approximately $114,000. Capital Bank & Trust Co grew its stake in shares of Celgene by 166.8% in the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 517 shares during the period. Finally, Guidant Wealth Advisors purchased a new stake in shares of Celgene in the 3rd quarter valued at approximately $119,000. 78.67% of the stock is owned by institutional investors.
Several analysts have recently weighed in on CELG shares. BMO Capital Markets increased their price target on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, November 17th. Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the company a “hold” rating in a research note on Wednesday, January 17th. William Blair reissued a “buy” rating on shares of Celgene in a research note on Wednesday, February 28th. Credit Suisse Group set a $129.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Thursday, March 1st. Finally, Stifel Nicolaus set a $130.00 price target on shares of Celgene and gave the company a “buy” rating in a research note on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $128.22.
Shares of Celgene Co. (NASDAQ:CELG) opened at $92.28 on Tuesday. The stock has a market cap of $69,410.00, a P/E ratio of 17.58, a price-to-earnings-growth ratio of 0.65 and a beta of 1.58. Celgene Co. has a fifty-two week low of $86.55 and a fifty-two week high of $147.17. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion for the quarter, compared to analyst estimates of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm’s quarterly revenue was up 16.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.61 EPS. equities analysts predict that Celgene Co. will post 7.66 earnings per share for the current year.
Celgene announced that its board has initiated a share buyback program on Wednesday, February 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
COPYRIGHT VIOLATION NOTICE: “AT Bancorp Grows Stake in Celgene Co. (CELG)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/13/at-bancorp-grows-stake-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.